Chromogranin A - serum marker for prostate cancer

Journal of the Pakistan Medical Association

Volumn 61, Issue 1, 2011, Pages 108-111

  Khan, Muhammad Owais ^a   Ather, Mohammad Hammad ^b  

^a DOW UNIVERSITY OF HEALTH SCIENCES   (Pakistan)

^b AGA KHAN UNIVERSITY   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; CHROMOGRANIN A; PROSTATE SPECIFIC ANTIGEN;

CANCER HORMONE THERAPY; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; DISEASE ASSOCIATION; HUMAN; NEUROENDOCRINE TUMOR; NEUROSECRETORY CELL; PREDICTION; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVIEW; SURVIVAL RATE;

BIOPSY; CHROMOGRANIN A; HUMANS; MALE; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 78651240858     PISSN: 00309982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (16)

1. Theodorescu D, Krupski T L. Prostate Cancer: Biology, Diagnosis, Pathology, Staging and Natural History. (Online) (Cited 2009 February 9). Available from URL: www.medscape.com.
2. Mehrabi S, Shirhzi HRG, Rasti M. Normal serum prostate specific antigen levels in men in Yasuj province, Islamic Republic of Iran. Eastern Mediterranean Health J 2005; 13: 1190-4.
3. Catalona WJ, Loeb. The PSA Era is not Over for Prostate Cancer. European Urology 2005; 48: 541-5.
4. Aziz Z, Sana S, Saeed S, Akram M. Institution based tumour registry from Punjab: Five year data based analysis. J Pak Med Assoc 2003; 53; 350-3.
5. Shah SIH, Khalid M, Sial SH. Metastatic Prostate Cancer; Is it justified to determine serum acid Phosphatase? The Professional; 8: 1-3.
6. Pusulari BB, Akbar RA, Bhatti M, Moeen-ul-Haq S. Hypocalcemia with bony metastases in prostate cancer. J Ayub Med Coll Abbottabad 2008; 20: 138-9.
7. Haneef M, Zaidi P, Kamal S, Idrees S, Rasool SA. Significance of prostate specific antigen in prostate cancer patients and in non cancerous prostatic disease patients. J Pak Med Assoc 2007; 57: 248-9.
8. Naz S, Ahmed S, Ghafoor F, Butt NS, Akhtar MW. Free and total Prostate specific antigen in benign prostatic hyperplasia and prostate cancer. J Coll Phys Surg Pak 2004; 14: 69-71.
9. Zhang WM, Finne P, Auvinen A, Leinonen J, Maattanen L, Ranniko S, et al. Use of complex between PSA and alpha 1 prosteanus inhibitor for screening prostate cancer. J Urology 2000; 164: 1956-60.
10. Iqbal N, Chaughtai N. Evaluation of the diagnostic use of free prostate specific antigen/total prostate specific antigen ratio in detecting prostate cancer. J Pak Med Assoc 2005; 55: 318-20.
11. Campana D, Nori F, Piscitelli L, Morselli-Labate AM, Pezzilli R, Corinaldesi R, Tomassetti P. Chromogranin A: Is It a Useful Marker of Neuroendocrine Tumours? J Clinical Oncology 2007; 25: 1967.
12. Isshiki S, Akakura K, Komiya A, Suzuki H, Kamiya N, Ito H. Chromogranin A concentration as a Serum Marker to Predict Prognosis after Endocrine Therapy for Prostate Cancer. J Urology 2002; 167: 512-4.
13. Schürmann G, Raeth U, Wiedenmann B, Buhr H, Herfarth C. Serum chromogranin A in the diagnosis and follow-up of neuroendocrine tumours ofthe gastroenteropancreatic tract. World J Surg 1992; 16: 697-701.
14. Online Cited 2009 July30. Available from URL: http://www.phoenix5.org/articles/ReutersChromoA022602.html.
15. Online Cited 2009 July30. Available from URL: http://www.prostateforum.com/article-02-23-09.html.
16. Sasakia T, Komiyab A, Suzukia H, Shimbob M, Uedab T, Akakurac K, Ichikawa T. Changesin Chromogranin A Serum Levels During Endocrine Therapy in Metastatic Prostate Cancer Patients; European Urol 2005; 48: 224-30.